Dipeptidylpeptidase-4 levels and DPP4 gene polymorphisms in patients with COVID-19. Association with disease and with severity

Autor: Gilberto Vargas-Alarcón, José Manuel Fragoso, Fausto Sánchez-Muñoz, Adrian Hernández-Díaz Couder, Carlos Alfonso Guzmán-Martín, Rosalinda Posadas-Sánchez, Gustavo Rojas-Velasco
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Adult
Male
medicine.medical_specialty
medicine.medical_treatment
Dipeptidyl Peptidase 4
Disease
Fibrinogen
030226 pharmacology & pharmacy
Gastroenterology
Polymorphism
Single Nucleotide
Severity of Illness Index
General Biochemistry
Genetics and Molecular Biology
Article
03 medical and health sciences
0302 clinical medicine
Gene Frequency
Polymorphism (computer science)
Internal medicine
Severity of illness
Genotype
Medicine
Severe acute respiratory syndrome coronavirus 2
Humans
General Pharmacology
Toxicology and Pharmaceutics
Allele frequency
Dipeptidylpeptidase-4
Mexico
COVID-19 disease
Aged
Mechanical ventilation
business.industry
Angiotensin converting enzyme-2
SARS-CoV-2
Albumin
COVID-19
General Medicine
Middle Aged
030104 developmental biology
Female
Angiotensin-Converting Enzyme 2
business
Polymorphisms
medicine.drug
Zdroj: Life Sciences
ISSN: 1879-0631
0024-3205
Popis: BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes de COVID-19 disease use as a principal receptor the angiotensin-converting enzyme-2 (ACE2). It has been suggested that dipeptidyl peptidase-4 (DPP4) can be another possible receptor for this virus. The present study aimed to establish if the DPP4 levels and DPP4 polymorphisms are associated with COVID-19 disease and its severity. METHODS: The study included 107 COVID-19 patients and 263 matched-healthy controls. Fifty patients required invasive mechanical ventilation. The DPP4 was quantified in serum using the Bioplex system. Based on the previous results and the functional prediction analysis, we select for the study 5 DPP4 polymorphisms (rs12617336, rs12617656, rs1558957, rs3788979, and rs17574) and these were determined using the 5´exonuclease TaqMan assays. RESULTS: Low levels of DPP4 were observed in COVID-19 patients (46.5 [33.1-57.7] ng/mL) when compared to healthy controls (125.3 [100.3-157.3] ng/mL) (P
Databáze: OpenAIRE
Externí odkaz: